Table 2 Neuropathological features of whole cohort
|  | Females (n = 159) | Males (n = 263) | p value |
|---|---|---|---|
Postmortem interval, hours | 20.3 (27.6) | 19.9 (26.5) | 0.91 |
Lewy body pathology stage (%) |  |  | 0.92 |
 -Brainstem-predominant | 15 (9.4%) | 30 (11.4%) | |
 -Limbic (transitional) | 57 (35.8%) | 85 (32.3%) | |
 -Neocortical (diffuse) | 87 (54.7%) | 148 (56.3%) | |
Level of substantia nigra neuron loss (%) |  |  | 0.068 |
 -None | 28 (17.6%) | 38 (14.4%) | |
 -Mild | 58 (36.5%) | 82 (31.2%) | |
 -Moderate | 49 (30.8%) | 78 (29.7%) | |
 -Severe | 24 (15.1%) | 65 (24.7%) | |
Alzheimer’s disease neuropathologic change (%) |  |  | 0.084 |
 -None | 5 (3.1%) | 20 (7.6%) | |
 -Low | 20 (12.6%) | 41 (15.6%) | |
 -Intermediate | 39 (24.5%) | 66 (25.1%) | |
 -High | 94 (59.1%) | 133 (50.6%) | |
Thal amyloid phase | 4.11 (1.31) | 3.81 (1.55) | 0.088 |
Braak tau stage | 4.72 (1.58) | 4.31 (1.65) | 0.017* |
CERAD neuritic plaque score | 2.20 (1.06) | 2.12 (1.08) | 0.5 |
Presence of ischemic, hemorrhagic or vascular pathology (%) | 158 (99.4%) | 261 (99.6%) | 0.8 |